Description
AMBLE · RESEARCH PRODUCT INFORMATION
Product overview
Thymosin Alpha 1 is a peptide associated with thymic and immune-system research. The source discusses studies of immune responses and host-defense pathways. Research or medical literature about thymosin alpha 1 does not establish approval of this research-use vial.
For scientific research and development only. Intended for in-vitro laboratory work, not human or animal administration. Not for use as a medicine, diagnostic product, medical device, food, supplement or cosmetic. No dosing, injection or treatment instructions are provided.
Product specifications
| Quantity | 5 mg |
|---|---|
| Unit | 1 Vial |
| Physical Appearance | White powder |
| Salt form | Acetate |
| Supplier reference purity (not lot verification) | ≥96% |
| Sequence | Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn-OH |
| Source-reported molecular mass (units not stated) | 3108.32 |
| CAS NO. | 62304-98-7 |
| Source-listed laboratory solvents | Phosphate Buffered Saline Solution |
Product features
- Source-listed pack: 5 mg 1 Vial
- Source-listed presentation: White powder
These characteristics identify the supplier reference presentation. They are not independent testing or verification of the current Amble lot.
These are reference specifications reported on the corresponding Particle Peptides page, not independent analytical verification of an Amble lot. Confirm the received label, identity, formulation and batch documentation before laboratory use. Unlisted fields have not been invented.
Storage and handling
1. Research use and restrictions
For scientific research and development only. Intended for in-vitro laboratory work, not human or animal administration. Not for use as a medicine, diagnostic product, medical device, food, supplement or cosmetic. No dosing, injection or treatment instructions are provided.
Literature involving animals or clinical studies is background information only and does not authorize this product for those uses. Do not supply this material for human investigational use.
2. Peptides in transport
Follow the current product label and lot-specific transport documentation. A general supplier statement about transport stability is not a guarantee for every formulation, liquid, blend or Amble shipment. The source supplier lists shipping restrictions for: Canada, Croatia, Czech Republic, Iceland, Ireland, Luxemburg, Norway, Serbia, Switzerland. This is the supplier’s published list, not a complete legal assessment or a replacement for Amble’s shipping policy.
3. Storage of lyophilized peptides
The supplier gives general guidance to protect lyophilized peptides from light and moisture. Storage temperature and expiry must follow the actual formulation and lot documentation. Do not treat a generic storage-duration table as validated shelf-life data for this Amble product.
4. Storage of reconstituted peptides
Solution stability depends on sequence, formulation, solvent and handling. Use product-specific stability documentation and laboratory procedures rather than assuming the same refrigerated life for all peptides. The supplier’s Ipamorelin stability discussion cannot be extrapolated to other products without supporting data.
5. Storage of peptide solutions
Avoid unnecessary freeze–thaw cycling and follow the documented conditions for the exact solution. This page does not establish a validated shelf life after preparation. The listed solvent information is a supplier reference, not a patient-use or injection protocol.
Overview of published research
The corresponding source page discusses the topics below. They describe areas of investigation, not proven customer benefits, treatment indications or evidence that this particular Amble batch has been tested.
- Immune-cell regulation
- Host-defense and infection-related research
- Inflammatory signaling and immune responses
Interpretation depends on the study design, experimental material and model. The presence of a publication in a supplier bibliography is not an independent verification of the supplier’s interpretation or a guarantee of safety or effectiveness. No clinical doses or administration protocols are reproduced here.
Quality and documentation
Source attribution: the specifications and bibliography below refer to Particle Peptides. Amble branding does not turn the supplier’s studies or documents into Amble batch certifications.
View the corresponding supplier product page
- Supplier safety data sheet (MSDS)
- Supplier COA/test document — not verification of the current Amble lot
Document links are retained as supplier references. Confirm lot matching, document authenticity and applicability before relying on them; this update does not independently verify those documents.
Bibliography listed by the supplier (20 entries)
Bibliographic entries are attributed to the source page. Individual citations have not all been independently validated; consult the original publications and distinguish primary studies from secondary reports.
- A. Dominari at al., “Thymosin alpha 1: A comprehensive review of the literature”, 2020 Dec 15; 9(5): 67–78.
- R. King and C. Tuthill, “Immune Modulation with Thymosin Alpha 1 Treatment,” Vitam. Horm., vol. 102, pp. 151–178, 2016.
- C. Zhang, J. Zhou, K. Cai, W. Zhang, C. Liao, and C. Wang, “Gene cloning, expression and immune adjuvant properties of the recombinant fusion peptide Tα1-BLP on avian influenza inactivate virus vaccine,” Microb. Pathog., vol. 120, pp. 147–154, Jul. 2018.
- F. Pei, X. Guan, and J. Wu, “Thymosin alpha 1 treatment for patients with sepsis,” Expert Opin. Biol. Ther., vol. 18, no. sup1, pp. 71–76, 2018.
- G. Wang et al., “Immunopotentiator Thymosin Alpha-1 Promotes Neurogenesis and Cognition in the Developing Mouse via a Systemic Th1 Bias,” Neurosci. Bull., vol. 33, no. 6, pp. 675–684, Dec. 2017.
- L. Romani et al., “Thymosin α 1 activates dendritic cells for antifungal Th1 resistance through Toll-like receptor signaling,” Blood, vol. 103, no. 11, pp. 4232–4239, Jun. 2004.
- L. Romani et al., “Thymosin alpha1: an endogenous regulator of inflammation, immunity, and tolerance,” Ann. N. Y. Acad. Sci., vol. 1112, pp. 326–338, Sep. 2007.
- A. L. Goldstein and A. L. Goldstein, “From lab to bedside: emerging clinical applications of thymosin alpha 1,” Expert Opin. Biol. Ther., vol. 9, no. 5, pp. 593–608, May 2009.
- C. Matteucci et al., “Thymosin alpha 1 and HIV-1: recent advances and future perspectives,” Future Microbiol., vol. 12, pp. 141–155, 2017.
- C. Matteucci et al., “Thymosin α 1 potentiates the release by CD8(+) cells of soluble factors able to inhibit HIV-1 and human T lymphotropic virus 1 infection in vitro,” Expert Opin. Biol. Ther., vol. 15 Suppl 1, pp. S83-100, 2015.
- J. Kharazmi-Khorassani, A. Asoodeh, and H. Tanzadehpanah, “Antioxidant and angiotensin-converting enzyme (ACE) inhibitory activity of thymosin alpha-1 (Thα1) peptide,” Bioorganic Chem., vol. 87, pp. 743–752, Jun. 2019.
- J. Kharazmi-Khorassani and A. Asoodeh, “Thymosin alpha-1; a natural peptide inhibits cellular proliferation, cell migration, the level of reactive oxygen species and promotes the activity of antioxidant enzymes in human lung epithelial adenocarcinoma cell line (A549),” Environ. Toxicol., May 2019.
- M. Maio et al., “Large randomized study of thymosin alpha 1, interferon alfa, or both in combination with dacarbazine in patients with metastatic melanoma,” J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol., vol. 28, no. 10, pp. 1780–1787, Apr. 2010.
- R. Danielli, E. Fonsatti, L. Calabrò, A. M. Di Giacomo, and M. Maio, “Thymosin α1 in melanoma: from the clinical trial setting to the daily practice and beyond,” Ann. N. Y. Acad. Sci., vol. 1270, pp. 8–12, Oct. 2012.
- X. Shen et al., “Generation of a novel long-acting thymosin alpha1-Fc fusion protein and its efficacy for the inhibition of breast cancer in vivo,” Biomed. Pharmacother. Biomedecine Pharmacother., vol. 108, pp. 610–617, Dec. 2018.
- F. Wang, T. Yu, H. Zheng, and X. Lao, “Thymosin Alpha1-Fc Modulates the Immune System and Down-regulates the Progression of Melanoma and Breast Cancer with a Prolonged Half-life,” Sci. Rep., vol. 8, no. 1, p. 12351, Aug. 2018.
- Y. Xu et al., “Thymosin Alpha-1 Inhibits Complete Freund’s Adjuvant-Induced Pain and Production of Microglia-Mediated Pro-inflammatory Cytokines in Spinal Cord,” Neurosci. Bull., Feb. 2019.
- L. Romani et al., “Thymosin α1 represents a potential potent single-molecule-based therapy for cystic fibrosis,” Nat. Med., vol. 23, no. 5, pp. 590–600, May 2017.
- P. F. Day, M. Duggal, and H. Nazzal, “Interventions for treating traumatised permanent front teeth: avulsed (knocked out) and replanted,” Cochrane Database Syst. Rev., vol. 2, p. CD006542, 05 2019.
- M. Schmidt et al., “Design of a substrate-tailored peptiligase variant for the efficient synthesis of thymosin-α1,” Org. Biomol. Chem., vol. 16, no. 4, pp. 609–618, 24 2018.
Product questions and answers
What is Thymosin Alpha 1 5mg?
Thymosin Alpha 1 is a peptide associated with thymic and immune-system research. The source discusses studies of immune responses and host-defense pathways. Research or medical literature about thymosin alpha 1 does not establish approval of this research-use vial.
What quantity is listed for Thymosin Alpha 1 5mg?
The corresponding supplier reference lists 5 mg 1 Vial. This applies to the stated presentation only; other strengths and quantities are not included.
Which identity or formulation details matter for Thymosin Alpha 1 5mg?
The supplier provides 9 reference specification fields for this listing. Those fields and source documents are not an independent Amble batch certificate.
Does the linked documentation certify this Amble batch?
No Amble-lot certification is established by a supplier webpage or an unmatched COA. Confirm the laboratory report, exact batch number, identity and formulation before relying on the documentation.
What storage conditions are verified for Thymosin Alpha 1 5mg?
Follow the actual lot label and product-specific safety and stability documentation. Generic storage tables and studies on another peptide do not establish this product’s shelf life.
Is Thymosin Alpha 1 5mg intended for human use?
No. This is a research-use listing for in-vitro laboratory work, not human or animal administration. The page provides no dosing, injection or treatment instructions.
US online ordering information
Information for customers reviewing Thymosin Alpha 1 5mg online from the United States.
This is a research-use listing, not a patient treatment or a finished medicine. Do not use it for human or animal administration. Review the exact formulation and lot-matched documentation, and confirm jurisdiction-specific eligibility before placing any order.
Use the live price and stock display on this page and review the final checkout total. Delivery, tax and return conditions depend on the product and destination; do not assume a delivery date or eligibility from this page alone.
For product or ordering questions, email hello@joinamblehealth.com. Read the Amble terms of service or visit your Amble account.
Reviews
There are no reviews yet.